Sleeplessness. Night sweats. Anxiety. Irritability. Aches and pains.

Would smoking a little pot help women deal with these common symptoms of menopause?

A good number of middle-aged women apparently think so, because they've been turning to marijuana to help handle the change of life, a new study reports.

"Midlife women within the menopause transition period of their life are using cannabis, and they're using it for symptoms that tend to overlap with menopause," said lead researcher Katherine Babyn, a graduate student at the University of Alberta in Canada.

There's just one drawback -- little to no research has proven that pot can effectively treat menopause-related symptoms, said Dr. Stephanie Faubion, medical director of the North American Menopause Society (NAMS).

The Association of American Feed Control Officials (AAFCO) has provided an update on its position on the use of hemp and hemp byproducts in animal feed, calling for more research.

In the USA, animal feed is regulated at a federal level by the U.S. Food and Drug Administration – Center for Veterinary Medicine (FDA-CVM). AAFCO is a non-regulatory body promoting the uniform regulation of feed throughout the country, working on the recommendations of the FDA.

At a state level, feed is usually regulated by each state’s Department of Agriculture. An example of a state that has allowed some hemp to be used in animal feed is Montana, but livestock (pet and horses only) fed hemp in Montana cannot enter interstate or intrastate commerce as the animals would be considered “adulterated” at a federal level.

Hemp is not yet permitted at a federal level as a stock feed. In its latest position statement, AAFCO says while it understands the enthusiasm for using hemp, stakeholders need to consider “the potential adverse impact” of allowing it in animal food before necessary research is carried out and legal processes observed demonstrating it is safe.

“Rather than unilaterally approving the use of hemp as a feed ingredient, in conflict with AAFCO’s century-old model for animal food ingredient approval, advocates should support continued research and development, and promptly submit applications to AAFCO and the FDA for review and approval on a national level,” says the body.

More people are in the emergency room for uncontrollable vomiting, also known as cyclical vomiting syndrome (CVS), following marijuana legalization, according to a new study.

According to the analysis published Friday in JAMA Network Open and sponsored by The National Institute on Drug Abuse (NIDA), Colorado has seen over 800,000 emergency room reports of vomiting between 2013 and 2018, a 29 percent uptick since the state legalized marijuana. The study also found that more than a third of the vomiting cases were in people under the age of 25.

Reviewing 820,778 patients in Colorado emergency departments, this study connected cannabis legalization with an increase in vomiting-related health care visits. This increase was seen primarily in Colorado counties without existing medical dispensaries prior to legalization.

This analysis suggested the vomiting is a symptom of cannabinoid hyperemesis syndrome (CHS), a condition marked by uncontrollable vomiting after cannabis use and usually occurs in long-term marijuana users. A 2020 study in Neurogastroenterology and Motility also found that 1 in 5 sufferers of cyclic vomiting syndrome were regular cannabis users.

Marijuana ironically has been used as an anti-nausea aid for those undergoing chemotherapy, where up to 75 percent experiencing it get nausea or vomiting.

The legalization of recreational marijuana use has broadly increased the availability of cannabis and the number of cannabis users. In the latest information (2019) compiled by SAMHSA, an estimated 31.5m individuals over 12 in the US used cannabis in the last month. These rates are growing at approximately 10% per year, with the largest growth in use by adults over 26 (19% growth in 2018-2019). However, growth in the sales of edible cannabis products has outpaced even these trends: sales of edible expanded 60% from 2019 to 2020 for an estimated market of $1.23 billion. (As Originally seen on Benzinga By: Nate Guzowski)

This rise in edible cannabis has had several unintended consequences, in particular a rise in the number of cases of accidental over ingestion. Edibles contain a range of different THC concentrations, including many with several times the average dose for an adult. Also the onset of drug effects for edibles is much longer than for smoked or vaped cannabis products, and this can lead to individuals overconsuming these products under the impression that they have under-dosed.

There is evidence that these cases of over-consumption have lead to an increase in the rates of acute cannabinoid intoxication (ACI) requiring medical attention. Poison control centers have documented a dramatic increase in the number of reports involving edible cannabis, rising from 8.4% to 31.2% of reports from 2017 to 2019.

This report also documented the increased risk to children from edibles, with these products making up 48% of reports involving children under 10, despite being only 11.1% of cannabis sales nationwide. The availability of gummies, cookies, brownies, and other sweets likely exacerbates the issue. ACI is a medical emergency in children and is associated with encephalopathy, coma, severe respiratory depression requiring ventilation, and even death. 

New Problems Require New Solutions

Anebulo Pharmaceuticals is developing a treatment to help address the issues of ACI from edibles and other products. The company’s lead compound ANEB-001 is an antagonist of the CB1 receptor responsible for the effects of cannabis and THC intoxication. ANEB-001 works by binding to and blocking these receptors from engaging THC and other cannabinoids (eg. synthetics like K2 or Spice). 

Amy Reid is serious about medical marijuana.

She’s a Wichita registered nurse and president of the Kansas Cannabis Coalition. She describes herself as a cannabis navigator for her patients, and she is all business when it comes to advocating for medical weed. I couldn’t help but chuckle when she told me the name of a sister organization, the Kansas Cannabis Chamber of Commerce. She asked me what was so funny.

Um, the name, I said, guilty as a schoolboy. The hard K, the alliteration, all ending with “chamber of commerce.” It was like no chamber I’d ever heard of, but the only one I might want to join.

It’s not funny, Reid told me. There are people in Kansas who need medical marijuana to relieve their pain, especially from cancer, and it’s far better than using opioids. It was an outrage, she said, that somebody living on the Missouri side of the river in Kansas City had safe and legal access to medical marijuana, while just a couple of blocks away in Kansas the same patients risk a felony conviction.

“We are simply asking our lawmakers to allow Kansas residents access to the therapeutic effects of this amazing plant,” Reid told me. “Three of our four neighboring states allow this, and it’s time Kansas stepped out of the ‘Reefer Madness’ mentality and allowed patients to have a choice.”

In just a few weeks, licenced veterinarians in the US state of Nevada will be able to recommend and administer hemp and cannabidiol (CBD) products for the treatment of animals.

While CBD pet products are widely available in the USA, in many states veterinarians are not permitted to administer them or even discuss cannabidiol with pet owners. In other states laws are unclear, which makes vets nervous about the potential for prosecution or other action.

But back in May this year, Nevada Governor Steve Sisolak signed Assembly Bill 101 into law, which permits veterinarians in that state to administer products containing hemp or CBD with not more than 0.3 percent THC. Aside from the legal side of things, animals such as dogs and cats are particularly sensitive to THC and too much can cause health problems.

From the beginning of next month – when the Act comes into effect – veterinarians will also be able to freely discuss such products with pet owners and the Nevada State Board of Veterinary Medical Examiners is prohibited against taking action against a licensed veterinarian, or the facility in which he/she operates, for such activities.

It not as though the NVMA was opposed to CBD. It helped write AB 101, which the Nevada Veterinary Medical Association also supported. Before the Bill hit the Governor’s desk, it faced zero opposition – not a single “no” vote.

A recent report about a sharp rise in Wisconsin’s alcohol sales got a lot of attention. But it didn’t answer the question of who was consuming all the beer, brandy and wine that’s leaving store shelves at a faster clip than it has since 1972.

It appears it might be mom and dad, along with grandpa and grandma, who are doing all the drinking. It's not young adults, at least not college students.

A new national report sponsored by the National Institute on Drug Abuse found "a substantial and significant drop" in current alcohol use among college students between 2019 and 2020.

The Monitoring the Future study, however, found marijuana use among college-age adults in 2020 across the nation was at a historic high not seen since the 1980s.

Wisconsin is no exception.

Cannabis edibles are undoubtedly one of the most popular products to consume these days. Many people are trying to get their hands on some cannabis edibles because of a rewarding experience. Many users say that they are moving away from smoking cannabis in the traditional way. There are a few reasons why cannabis edibles are becoming increasingly popular. Not only are cannabis edibles easy to store and consume, but they are also easy to carry around. Taking cannabis edibles can also have many recreational and medicinal benefits that can treat many issues. If you want to try cannabis edibles, you can Get Kushto satisfy your needs. Let us look at how cannabis edibles affect you.

What are Cannabis Edibles?

A popular way of taking cannabis these days is by consuming cannabis edibles. Manufacturers take the marijuana plant, and they use it to make edible products such as cannabis brownies and cannabis gummies. A recent trend is motivating many people to move away from the traditional way of smoking cannabis. Cannabis edibles are arguably the most popular alternative for smoking cannabis, and there are good reasons behind this. The first attractive quality when talking about cannabis edibles is how users can highly customize their experience. Users have the option to go for a variety of cannabis edibles. You can get cannabis brownies, cannabis cakes, cannabis gummies, cannabis chocolates, and many other popular products. The excellent quality of cannabis edibles is that they are available in stores, and you can also make them at home. When users take cannabis edibles, they are in complete control of the experience. Many users do not enjoy the raw taste of cannabis. Therefore cannabis edibles prove to be an excellent alternative.

Another key reason behind the popularity of cannabis edibles is how discreetly users can consume them. Many cannabis users report that it is much easier to take cannabis edibles rather than smoke cannabis regularly. Smoking can be a significant inconvenience for users and even for people around them. There are also a lot of restrictions regarding where users can smoke. The struggles of finding a lighter or a matchstick do not make the experience any better.

When it comes to cannabis edibles, there is little to no preparation needed. There are also no restrictions as to where you can consume cannabis edibles. You can discreetly carry your cannabis edibles without anyone finding out. Especially if your cannabis edibles are in the form of brownies or gummies, no one will ever be suspicious of you.

What are the Benefits of Taking Cannabis Edibles?

Cannabis edibles can help you experience all the benefits of consuming cannabis. These benefits can range from recreational to medicinal. For example, you can get help with treating chronic pain, anxiety, depression, and several other health conditions. You can also get help with clearing your mind and relaxing. In the modern world, there are so many different issues that we face daily. It can understandably be overwhelming to tackle everything at once. When you consume cannabis edibles, you can take a step back and relax. Taking cannabis edibles will give you some much-needed space, and you will end up making better decisions. Taking cannabis edibles can also help you treat inflammation, and in some cases, it can also address some symptoms that arise due to cancer.

The German process is unlike anything foreigners have ever experienced before—with twists and turns at every step that frequently defy logic.

The German medical cannabis market is one of the largest in the world. Indeed, as of 2021, it is not only the largest market in Europe, but also responsible for driving cultivation plans across many sunnier and lower labor cost locales. This is true of both countries in the European Union (EU) and further flung spots, all hoping to export cannabis to a country, which so far has not, by design, been able to domestically source the medical cannabis consumed in the country. 

All well and good—but this is the good news. 

In fact, the pharmaceutical infrastructure that faces medical cannabis companies is far from either clear cut or easy to navigate. Here is why.

Cannabis is Defined by Law as a Controlled Narcotic Drug

The first issue facing all distributors in the German market, is that cannabis, legally, is defined as a narcotic at a federal level. To date, despite a decision on the European level last fall, this also includes low THC hemp—which has led to a number of lawsuits and embarrassing contretemps of late even on the non-medical, commercial level. 

Beyond this, however, cannabis as medicine is clearly now present in the system—but merely importing and or registering strains and brands (no matter who makes them or where such flower or products come from) is far from enough to get sales.

There is no better place in Florida to hold a Sacred Mushroom Summit than Gainesville.

The city gave rise to the famed Gainesville Green marijuana strain. People gladly squished through pastures mined with cow patties in search of mind-altering fungi. Joints were regularly smoked at college football games. And ecstasy-fueled raves at Simon's downtown drew elite techno DJs from Europe.

The summit, set for Friday through Sunday at the Thomas Center, will feature lectures and presentations on the use of hallucinogens of the Americas including ayahuasca, cannabis and peyote.

Topics will include medical use, psychological, anthropological and historic aspects of the drugs, religious freedom and legal issues.

“There is a whole lot going on right now in this area,” said organizer Tom Lane, who has written books on historic use of psychoactives. “This type of medicine pre-dates the colonial days. Indigenous sages were using this in Mexico way before the colonials got here.”

Hallucinogens are going through a revival. They were widely studied through the mid-1900s for medical and therapeutic value but got ground up in the war on drugs later in the century after LSD, marijuana and mushrooms were used recreationally.

A South Dakota legislative subcommittee recommended on Wednesday that the state’s medical marijuana regulations prohibit the home cultivation by patients.

A recommendation from the South Dakota Legislative subcommittee comes from a group of lawmakers working to draft rules to limit provisions of Initiated Measure 26 (IM26), a ballot measure to legalize medical marijuana that was passed by nearly 70 percent of South Dakota voters in the November 2020 general election.

The announcement came from a subgroup of the South Dakota Marijuana Summer Study Committee, a panel of lawmakers that was assembled to make changes to IM 26. In addition to eliminating home cultivation, the panel is considering proposals including repealing legal protections for marijuana businesses and their attorneys and another that would allow local governments to prohibit cannabis businesses to operate in their jurisdictions.

“We’re not here to say no to marijuana,” said Republican state Representative Carl Perry. “What we’re here doing is making sure it’s good [policy].”

South Dakota Voters Approved Medical Marijuana in November

Following the passage of IM 26 and a separate ballot measure to legalize cannabis for use by adults, South Dakota Governor Kristi Noem announced that implementing the medical marijuana initiative would be delayed. The delay came despite provisions of state law that approved ballot measures take effect on July 1 of the year following passage, which would have been this year.

“We are working diligently to get IM 26 implemented safely and correctly,” Noem said in a statement released by her office. “The feasibility of getting this program up and running well will take additional time. I am thankful to our legislative leaders for helping make sure that we do this right.”

For the longest time, marijuana was seen as pathological in the eyes of the research community. This was not because researchers believed so, but rather that the vast majority of the grants were given to studies that supported this premise.

These days, we’re changing our tune and some scientists and medical researchers are asking for a new standard in cannabis research. In fact, in this Psychiatric Times article, Dr. John Miller points out some glaring issues with cannabinoid research that needs to be addressed.

Here, I’ll be walking you through the basics of the article, focusing on his 10 suggestions for cannabinoid research.

One of the issues that Dr. Miller pointed out is that cannabis isn’t a single drug. Unlike all other drug research that focuses on a singular substance, cannabis is comprised of over 500 compounds that include cannabinoids, terpenoids, and flavonoids.

Perhaps there is a greater ratio of THC:CBD in one strain compared to another, which would undoubtedly affect the outcome of a study. Maybe there’s a greater presence of myrcene, a monoterpene that is often found in cannabis.

Psoriasis is a chronic medical condition that has severe implications on an individual’s physical and mental health, which is why the treatment plan has to be holistic and practical.

Approximately 125 million people worldwide have psoriasis. The widespread prevalence of this skin condition makes it a global health concern, which is why experts have been working rigorously to find a solution for this disease.

There is no proven cure for psoriasis, but there are some ways to treat or manage the symptoms of this disease. One solution that has been discovered recently and has become increasingly popular is CBD oils on the skin affected by psoriasis to heal and consume the CBD oil orally to help with the immune system.

If you have psoriasis and are looking into using CBD oil for your treatment, wondering what the possibilities of this treatment are, here is all the information you need to make up your mind and understand this new medical approach. Let’s talk about the symptoms of psoriasis and how CBD oils can target them before discussing the effectiveness of CBD oils in treating psoriasis.

Delta 9 Cannabis Inc. (OTCMKTS: DLTNF) has announced the appointment of David Kideckel to the newly created EVP Head of Strategy, Corporate Development & Capital Markets position to spearhead the company’s next growth expansion phase. David has around 20 years of combined experience in capital markets and industry. 

Delta 9 appoints David Kideckel to head the expansion phase 

Delta 9 CEO John Arbuthnot said, “I am extremely pleased to welcome David to our team, propelling our capital markets strategy and reach, through his wealth of experience. David was one of the leading cannabis analysts and has an exceptional network of contacts with an in-depth knowledge of the cannabis industry and its subsectors. David’s appointment reflects our commitment to having best-in-class talent to advance the Company’s growth trajectory strategically and expeditiously.”

David commented, “Of all the companies I have evaluated over the last several years, Delta 9 has incredible potential and I’m proud to join a seasoned team that is on the verge of steady and continuous growth within an explosive industry.”

Amyris launches first of the Terasana Clinical skincare products 

Amyris Inc. (NASDAQ: AMRS) has launched the Terasana Clinical clean skincare brand. The launch is the first of the three brand launches the company anticipates launching this summer. The first skincare brand, Clear + Control Healthy Skin Serum, addresses irritation, skin flaking, dry skin, and redness. The proprietary formulation in the product combines Cannabigerol (CBG) and Squalane. 

CEO John Melo said, “CBG has a variety of proven skin benefits and through our well-established fermentation technology, we are able to manufacture CBG at scale and at a much lower cost than existing alternatives. We believe that clean CBG has opened up new avenues for innovation in sustainable and effective skincare and that it has the potential to be a breakthrough in addressing the acne market. We are on track to launch three new clean beauty consumer brands this month.”

New Israeli clinical trials will examine the safety and efficacy of cannabis-based treatments for some of the most painful and persistent gynecological conditions faced by women.

The trials, expected in early 2022, will test cannabis-based pharmacology products developed by Gynica, a Jerusalem-based femtech (female technology) startup that believes that the active ingredients in the plant can ease painful conditions in the female reproductive system such as dysmenorrhea, or painful menstruation, and endometriosis.

Conventional treatments like over-the-counter painkillers, hormone therapy, and even surgical intervention can be insufficient or even pose their own health detriments in the case of endometriosis, an often agonizing disorder that occurs when tissue similar to that which normally lines the uterus – the endometrium – begins to grow outside the organ.

Gynica says it is hoping to meet unaddressed needs in women’s health by developing cannabis-based solutions for these conditions.

Veterans in vulnerable subgroups are at a higher risk of developing cannabis use disorder (CUD) or consuming cannabis for adult (recreational or non-medical) use, according to a new study from researchers at Pennsylvania’s Center of Excellence in Substance Addiction Treatment and Education at the Corporal Michael J. Crescenz VA Medical Center.

The results indicate the prevalence of CUD and adult cannabis use over the past twelve months to be 1.8 per cent and 7.3 per cent, respectively, whereas lifetime prevalence clocked in at 5.7 per cent and 32.5 per cent. Past 12-month and lifetime CUD prevalence in adult cannabis consumers were calculated at 24.4 per cent and 17.4 per cent, respectively.Researchers also found correlations between CUD and/or nonmedical cannabis use and certain sociodemographic groups, including those who earn a lower income, are male, are young, are single (unmarried), and reside in a state with established medical cannabis legislation.

“Nonmedical cannabis use and use disorder were associated with most psychiatric and substance use disorders examined,” the authors note.

Lead author Kendall C. Browne, Ph.D., concluded that the findings are indicative of a need for increased screening and resources for veterans at a higher risk of developing CUD.

“Among veterans, the odds of nonmedical cannabis use and use disorder were elevated among vulnerable subgroups, including those with lower income or psychiatric disorders and among survey participants residing in states with medical marijuana laws,” Browne concluded.  “The study findings highlight the need for clinical attention (e.g., screening, assessment) and ongoing monitoring among veterans in the context of increasing legalization of cannabis.”